In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters

Life Sciences

Volumn 79, Issue 4, 2006, Pages 317-323

  Tóth, Orsolya ^a   Szabó, Csaba ^b,c   Kecskés, Marianna ^a   Pótó, László ^a   Nagy, Ágnes ^a   Losonczy, Hajna ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b INOTEK CORPORATION   (United States)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Antithrombotic therapy; Drug interaction; Myocardial ischemia; PARP inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ALTEPLASE; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; EPTIFIBATIDE; HEPARIN; INO 1001; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; SODIUM CHLORIDE; TIROFIBAN;

ANTICOAGULATION; ARTICLE; BLOOD CLOT LYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; EUGLOBULIN LYSIS TEST; FEMALE; HEMOSTASIS; HUMAN; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; STATISTICAL ANALYSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA;

ASPIRIN; BLOOD COAGULATION; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ENZYME INHIBITORS; FACTOR XA; FEMALE; HEPARIN; HUMANS; INDOLES; MALE; PARTIAL THROMBOPLASTIN TIME; PEPTIDES; PLATELET AGGREGATION INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; TISSUE PLASMINOGEN ACTIVATOR; TYROSINE;

EID: 33744790313     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.01.007     Document Type: Article

References (30)

1. Alexy T., Toth A., Marton Z., Horvath B., Koltai K., Feher G., Kesmarky G., Kalai T., Hideg K., Sumegi B., and Toth K. Inhibition of ADP-evoked platelet aggregation by selected poly(ADP-ribose) polymerase inhibitors. Journal of Cardiovascular Pharmacology 43 3 (2004) 423-431
2. Born G.V., and Cross M.J. Effect of adenosine diphosphate on the concentration of platelets in circulating blood. Nature 197 (1963) 974-976
3. Boudjeltia K.Z., Cauchie P., Remacle C., Guillaume M., Brohee D., Hubert J.L., and Vanhaeverbeek M. A new device for measurement of fibrin clot lysis: application to the euglobulin clot lysis time. BioMed Central Biotechnology 2 (2002) 8
4. Chatterjee P.K., Cuzzocrea S., and Thiemermann C. Inhibitors of poly (ADP-ribose) synthetase protect rat proximal tubular cells against oxidant stress. Kidney International 56 3 (1999) 973-984
5. Fabris F., Ahmad S., Cella G., Jeske W.P., Walenga J.M., and Fareed J. Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications - a review. Archives of Pathology and Laboratory Medicine 124 11 (2000) 1657-1666
6. Frantz B., and O'Neill E.A. The effect of sodium salicylate and aspirin on NF-kappa B. Science 270 5244 (1995) 2017-2019
7. Harrington R.A., Becker R.C., Ezekowitz M., Meade T.W., O'Connor C.M., Vorchheimer D.A., and Guyatt G.H. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 513S-548S
8. Hauser B., Ehrmann U., Albicini M., Gröger M., Radermacher P., Szabó C., and Kick J. Selective poly(ADP-ribose)-polymerase inhibition affects neither DNA repair nor cell senescence after ischemia-reperfusion. In: Vincent J.L. (Ed). 25th International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, March 21-25, 2005. Critical Care vol. 9 (Suppl 1) (2005) 199
9. Hemmendinger S., Beretz A., Lanza F., and Cazenave J.P. Methods of studying platelet function. Biological markers of the activation of human platelets in vivo and in vitro. Annales de Biologie Clinique (Paris) 44 4 (1986) 347-352
10. Jagtap P., and Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. National Reviews. Drug Discovery 4 5 (2005) 421-440
11. Jagtap P., Baloglu E., Southan G.J., Mabley J.G., Li H., Zhou J., van Duzer J., Salzman A.L., and Szabó Cs. Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. Journal of Medicinal Chemistry 48 16 (2005) 5100-5103
12. Jung J.S., Park M.Y., Lee R.H., Jun J.S., and Kim Y.K. Protection against hydrogen peroxide induced injury in renal proximal tubule cell lines by inhibition of poly(ADP-ribose) synthase. Kidney and Blood Pressure Research 23 1 (2000) 14-19
13. Khan T.A., Ruel M., Bianchi C., Voisine P., Komjati K., Szabo C., and Sellke F.W. Poly(ADP-ribose) polymerase inhibition improves postischemic myocardial function after cardioplegia-cardiopulmonary bypass. Journal of American College of Surgery 197 2 (2003) 270-277
14. Komjati K., Mabley J.G., Virag L., Southan G.J., Salzman A.L., and Szabo C. Poly(ADP-ribose) polymerase inhibition protect neurons and the white matter and regulates the translocation of apoptosis-inducing factor in stroke. International Journal of Molecular Medicine 13 3 (2004) 373-382
15. Liaudet L., Szabo E., Timashpolsky L., Virag L., Cziraki A., and Szabo C. Suppression of poly (ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: long-term morphological and functional consequences. British Journal of Pharmacology 133 8 (2001) 1424-1430
16. Min S.K., Kim S.Y., Kim C.H., Woo J.S., Jung J.S., and Kim Y.K. Role of lipid peroxidation and poly(ADP-ribose) polymerase activation in oxidant-induced membrane transport dysfunction in opossum kidney cells. Toxicology and Applied Pharmacology 166 3 (2000) 196-202
17. Molinaro G., Gervais N., and Adam A. Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment. An in vitro experimental approach. Stroke 33 6 (2002) 1712-1716
18. Oliva P.B. Pathophysiology of acute myocardial infarction, 1981. Annales of Internal Medicine 94 2 (1981) 236-250
19. Pieper A.A., Walles T., Wei G., Clements E.E., Verma A., Snyder S.H., and Zweier J.L. Myocardial postischemic injury is reduced by polyADPripose polymerase-1 gene disruption. Molecular Medicine 6 4 (2000) 271-282
20. Seshiah P.N., Kereiakes D.J., Vasudevan S.S., Lopes N., Su B.Y., Flavahan N.A., and Goldschmidt-Clermont P.J. Activated monocytes induce smooth muscle cell death: role of macrophage colony-stimulating factor and cell contact. Circulation 105 2 (2002) 174-180
21. Szabados E., Fischer G.M., Gallyas Jr. F., Kispal G., and Sumegi B. Enhanced ADP-ribosylation and its diminution by lipoamide after ischemia-reperfusion in perfused rat heart. Free Radical Biology and Medicine 27 9-10 (1999) 1103-1113
22. Szabo C., Zingarelli B., O'Connor M., and Salzman A.L. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proceedings of the National Academy of Sciences of the United States of America 93 5 (1996) 1753-1758
23. Szabo G., Liaudet L., Hagl S., and Szabo C. Poly(ADP-ribose) polymerase activation in the reperfused myocardium. Cardiovascular Research 61 3 (2004) 471-480
24. Szabo G., Soos P., Mandera S., Heger U., Flechtenmacher C., Bahrle S., Seres L., Cziraki A., Gries A., Zsengeller Z., Vahl C.F., Hagl S., and Szabo C. INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation. Shock 21 5 (2004) 426-432
25. Thiemermann C., Bowes J., Myint F.P., and Vane J.R. Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proceedings of the National Academy of Sciences of the United States of America 94 2 (1997) 679-683
26. Virag L., and Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacological Reviews 54 3 (2002) 375-429
27. Xiao C.Y., Chen M., Zsengeller Z., Li H., Kiss L., Kollai M., and Szabo C. Poly(ADP-Ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure. Journal of Pharmacology and Experimental Therapeutics 312 3 (2005) 891-898
28. Yang Z., Zingarelli B., and Szabo C. Effect of genetic disruption of poly (ADP-ribose) synthetase on delayed production of inflammatory mediators and delayed necrosis during myocardial ischemia-reperfusion injury. Shock 13 1 (2000) 60-66
29. Zhang J., Dawson V.L., Dawson T.M., and Snyder S.H. Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science 263 5147 (1994) 687-689
30. Zingarelli B., Cuzzocrea S., Zsengeller Z., Salzman A.L., and Szabo C. Protection against myocardial ischemia and reperfusion injury by 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase. Cardiovascular Research 36 2 (1997) 205-215